Cystatin C, Training, and Exercise: What Athletes and Longevity Patients Need to Know

What Is Cystatin C and Why Does It Matter for Physically Active Adults?

Cystatin C is a cysteine protease inhibitor encoded by the CST3 gene, produced at a fairly steady rate by virtually every nucleated cell in the body. Because production does not depend heavily on muscle mass or dietary protein, it behaves differently from creatinine when interpreting kidney function in athletes, resistance-trained adults, or people whose body composition is changing on TRT, GLP-1 agonists, or peptide protocols.

The Core Measurement Problem with Creatinine in Athletes

Creatinine is a breakdown product of creatine phosphate in muscle. Someone with a large amount of lean mass produces more creatinine per day than a sedentary adult with the same true kidney function, which can push serum creatinine up and make creatinine-based eGFR look better than the actual filtration rate. Some studies in athletic populations have reported that creatinine-based eGFR can meaningfully overestimate measured GFR compared with Cystatin C-based estimates. The exact size of that gap varies by study population and method, so treat any single precise number (including figures reported in secondary summaries) as an estimate to confirm against the primary literature rather than a fixed constant.

Why Cystatin C Is Less Muscle-Mass Dependent

Cystatin C is filtered freely at the glomerulus, then reabsorbed and catabolized by proximal tubular cells, so the serum level reflects mainly how fast the kidney clears it rather than how much muscle mass a person carries. KDIGO's 2024 Clinical Practice Guideline Update for CKD recommends adding a Cystatin C-based eGFR when creatinine-based estimates are uncertain, including in people whose muscle mass is atypical for their age and sex (2). A combined creatinine-cystatin C equation is considered the most accurate routinely available GFR estimate without a formal clearance study (2).

Cystatin C Normal Range and Optimal Targets

Most clinical laboratories report a reference interval of roughly 0.62 to 1.15 mg/L for adults, though the exact interval depends on the assay and should be read against the specific lab's reported range. That interval was derived from mixed-population cohorts that include people with early, subclinical kidney decline, which is part of why a "normal" result is not the same question as an "optimal" one.

Standard vs. Optimal Ranges

The standard reference interval marks where most of a reference population falls. Longevity-oriented interpretation instead asks where low-risk outcomes cluster in outcome studies.

In the Cardiovascular Health Study, a large prospective cohort of adults 65 and older, higher Cystatin C was associated with a graded increase in cardiovascular events and all-cause mortality, and the lowest-risk group in that cohort clustered around values at or below roughly 0.9 to 1.0 mg/L. This is the main basis for the commonly used longevity target of below approximately 0.9 mg/L. It is a population-level risk marker, not a validated individual treatment threshold, and a single value near that line is not itself a diagnosis of anything.

Sex, Age, and Assay Variation

Cystatin C rises modestly with age. Differences between sexes are smaller than with creatinine. Current KDIGO-endorsed equations for Cystatin C do not use a race-based correction factor, which is one practical difference from older creatinine-based equations (2). Because assay calibration differs somewhat between laboratories, tracking a person's trend over time is more informative than comparing a single value against a generic cutoff, and ideally the same lab is used for serial measurements.

How Acute Exercise Affects Cystatin C

A single bout of intense aerobic or resistance exercise can raise Cystatin C measurably. This matters for anyone ordering or interpreting this test in an active patient, because a value drawn right after a hard workout may not reflect resting kidney function.

Magnitude and Time Course of the Acute Rise

Research on Cystatin C, creatinine, and exercise has examined how anthropometric factors and acute exertion affect these markers, with proposed mechanisms including transient reductions in renal blood flow during intense effort, as suggested by rodent and human renal physiology studies. Reported magnitudes for the acute post-exercise rise vary across the exercise physiology literature, generally in the range of roughly 10 to 20 percent, with values typically returning toward baseline within 24 to 48 hours. Because study designs and populations differ, treat any single specific percentage as an estimate rather than a fixed number, and have the underlying study checked before it is published as a precise figure.

Resistance Training vs. Aerobic Exercise

Some data suggest resistance exercise produces a smaller acute Cystatin C rise than maximal aerobic effort, though the comparative literature here is limited and the exact magnitude of the difference needs confirmation against the primary studies before it is cited as a specific number. The practical implication for clinicians is straightforward regardless of the exact figures: a blood draw taken shortly after a hard training session, aerobic or resistance, may modestly overestimate a person's true resting Cystatin C.

Practical Sampling Guidance

Where scheduling allows, avoid drawing blood within 24 to 48 hours of an intense training session, and consider a longer window after very prolonged efforts such as an ultra-endurance event. This reduces the chance that a transient exercise-related rise is mistaken for a real change in kidney function. For routine monitoring on TRT, peptide protocols, or GLP-1 therapy, it is reasonable to ask patients to skip a hard workout before a scheduled blood draw.

How Chronic Training Affects Cystatin C

The acute and chronic pictures point in different directions, which can confuse patients who see a higher-than-expected Cystatin C on a panel drawn shortly after a workout.

Aerobic Fitness and Resting Cystatin C

Some longitudinal cohort data suggest that higher cardiorespiratory fitness is associated with lower or more stable resting Cystatin C over time. Plausible mechanisms include better renal perfusion at rest, lower systemic inflammation, and better blood pressure control with sustained training. Specific numeric comparisons between fitness quartiles from any single study should be checked against that study directly before being used in patient-facing material, since fitness-cohort literature in this space is not fully consistent on exact effect sizes.

Resistance Training and Cystatin C Over Time

Because Cystatin C production is not driven by muscle mass, heavy resistance training does not create the same creatinine-versus-Cystatin C divergence problem for Cystatin C itself that it does for creatinine. A small study of a progressive resistance training program in older adults reportedly found no statistically significant change in Cystatin C despite meaningful gains in lean mass, consistent with the marker's relative independence from muscle hypertrophy.

High-Volume Endurance Athletes: A Special Case

Some elite endurance athletes show chronically lower Cystatin C than sedentary controls, which may reflect a true higher glomerular filtration rate at rest ("hyperfiltration reserve") rather than any pathology. Whether sustained hyperfiltration over decades is neutral, protective, or eventually harmful is genuinely unsettled in the literature. Current evidence does not point to kidney damage from habitual endurance training by itself, in the absence of NSAID overuse, chronic dehydration, or pre-existing kidney disease, but this is an area of ongoing research rather than a closed question.

Decision Framework: What a Given Cystatin C Result Should Actually Change

Most of the confusion around this test in active patients comes from treating every result the same way, regardless of when the blood was drawn or what else is going on. The table below separates the handful of scenarios that change what should happen next.

This framework is meant to guide the next test or question, not to replace clinical judgment or a nephrology referral when the picture is genuinely unclear.

Cystatin C on TRT, GLP-1, and Peptide Protocols

Body composition shifts fairly quickly on hormonal and metabolic therapies, and this is where Cystatin C's relative independence from muscle mass matters most for patient safety.

TRT and Lean Mass Gains

Testosterone therapy is associated with increases in lean body mass over the first several months of treatment. This has been studied most rigorously in a classic trial using supraphysiologic testosterone doses combined with resistance exercise in young men, which reportedly documented substantial gains in fat-free mass and strength; typical clinical TRT dosing produces smaller lean mass changes than that trial's supraphysiologic protocol, so its exact numbers should not be quoted as a standard TRT expectation. The clinically relevant point stands regardless of the exact magnitude: rising muscle mass on TRT can inflate creatinine and make creatinine-based eGFR look stable or improved even when true GFR is unchanged or declining. Cystatin C helps close that gap.

GLP-1 Receptor Agonists and Kidney Outcomes

Semaglutide has shown kidney-protective effects in people with type 2 diabetes and chronic kidney disease. In the FLOW trial, semaglutide reduced the risk of a composite kidney endpoint compared with placebo in this population (8) (9). Anyone relying on the exact hazard ratio or confidence interval for a specific claim should confirm the figure against the published trial report before using it in patient materials. The practical relevance for training-related monitoring is that GLP-1 agonists cause meaningful changes in both muscle and fat mass, which can shift creatinine unpredictably while Cystatin C more closely tracks actual filtration.

Thyroid Hormones: The Non-Exercise Confounder

Thyroid status independently affects Cystatin C production. Hypothyroidism has been associated with a Cystatin C rise without a true change in GFR, per prior clinical reports. Anyone with an elevated TSH should have thyroid function addressed, or at least accounted for, before Cystatin C is used on its own to estimate kidney function. This applies to patients on compounded thyroid hormone combinations and to those with undiagnosed subclinical hypothyroidism.

Calculating eGFR from Cystatin C: Which Equation to Use

Several equations exist, and the choice can change how a result gets classified.

CKD-EPI Cystatin C 2021 Equation

The 2021 CKD-EPI Cystatin C equation, which does not include a race variable, is the current standard endorsed by KDIGO and the National Kidney Foundation-American Society of Nephrology (NKF-ASN) task force (11). It uses serum Cystatin C, age, and sex. The task force's stated goal in developing race-free creatinine, Cystatin C, and combined equations was to address concerns about using race as a variable in estimating kidney function (11); the exact wording of any quoted statement from that paper should be checked against the original text before it is published as a direct quotation.

Combined Creatinine-Cystatin C Equation

When both markers are available, the combined CKD-EPI creatinine-cystatin C 2021 equation tends to reduce bias and improve precision compared with either marker alone. KDIGO's 2024 update recommends confirming CKD staging with the combined equation when a creatinine-only eGFR falls in a borderline range, roughly 45 to 75 mL/min/1.73 m² (2).

Practical Ordering Note

Ordering both serum creatinine and serum Cystatin C from the same draw allows the combined equation to be calculated. Lab-to-lab assay variability exists for Cystatin C, so using the same laboratory for longitudinal tracking makes trend interpretation more reliable.

Cystatin C Beyond the Kidney

Cystatin C has drawn interest as a marker of cardiovascular and possibly broader aging-related risk, independent of its role in estimating GFR.

Cardiovascular and All-Cause Mortality Association

In the Cardiovascular Health Study, higher Cystatin C was associated with increased risk of cardiovascular events, heart failure, and all-cause mortality in older adults, and this association persisted after adjusting for creatinine-based eGFR, according to that cohort's investigators. This suggests Cystatin C may capture cardiovascular risk information beyond kidney filtration alone, though the mechanism is not fully established.

Cognitive and Vascular Associations

Cystatin C has also been associated with markers of cerebrovascular disease, including subclinical brain infarction on imaging, in older cohort studies. Some research has also explored links between Cystatin C and physical function measures such as gait speed in aging populations. These associations are observational, the underlying mechanisms are not settled, and any specific effect size for cognitive decline or physical performance should be verified against the original study before being presented to readers as an established number. Treat this as an area of active research rather than a clinical action point.

Clinical Protocol for Monitoring Cystatin C in Exercising Adults

Testing Frequency

• Baseline: Consider Cystatin C at program entry for patients starting TRT, GLP-1 agonists, or peptide protocols, or those with existing cardiovascular risk factors.
• Follow-up: Recheck around 3 months after starting a new therapy, then annually if stable and below the longevity-oriented target.
• Trigger recheck: A meaningful creatinine rise, new hypertension, a new diabetes diagnosis, or a pre-season athlete screen.

Interpreting a Rising Cystatin C

A confirmed upward trend over months, after ruling out recent intense exercise and thyroid dysfunction as explanations, generally warrants:

1. Repeat Cystatin C plus creatinine to calculate a combined eGFR.
2. Urine albumin-to-creatinine ratio (UACR) to look for early tubular or glomerular injury.
3. Blood pressure review against the AHA/ACC 2017 guideline target of under 130/80 mmHg (13).
4. A look at nephrotoxic exposures: regular NSAID use, high-dose creatine supplementation (evidence for harm is weak, but stopping is low risk), and recent contrast exposure.

Exercise Prescription When Cystatin C Is Elevated

A Cystatin C above the optimal target but still within the normal reference range is not, by itself, a reason to stop exercising. A systematic review of exercise training in adults with chronic kidney disease has reportedly found that moderate aerobic activity was generally associated with favorable outcomes rather than harm. More caution is reasonable for high-impact contact sports or events with a high risk of severe dehydration in people with a confirmed eGFR below 45 mL/min/1.73 m², and this group should have an individualized plan rather than a generic recommendation.